Nusinersen is approved for use in both pediatric and adult patients with all types of SMA. However, it has shown the most significant benefits in infants diagnosed with SMA Type 1, the most severe form of the disease, typically presenting symptoms before 6 months of age. Early diagnosis and intervention with Nusinersen have been shown to improve motor function and increase survival rates.
